Launch of Beacon Medical(TM) High-Dose CBD Oil Toronto, Ontario--(Newsfile Corp. - November 23, 2021) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of medical cannabis products and patient services, and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms") and ABcann Medicinals Inc., today announced the launch of its newest medical cannabis product formulation: high-dose cannabidiol (CBD) oil under its Beacon Medical™ brand.
Beacon Medical™ 2:100 high-dose CBD oil is a distillate-based cannabis oil containing 100 mg CBD and less than 2 mg tetrahydrocannabinol (THC). The entire family of Beacon Medical™ oil products are formulated using a non-GMO, food-grade medium-chain triglycerides (MCT) carrier oil which results in the final product being both scentless and flavourless in taste.
"With our commitment to the medical cannabis market, the team at VIVO aspires to deliver premium cannabinoid-based medical products to our patients, and the Beacon Medical™ CBD+ | O has been launched in response to patient insights our team has collected over time," commented Ray Laflamme, Canna Farms' Co-Founder and VIVO's Chief Executive Officer. "We recognize that many of our patients are looking for products that meet their individualized needs, and this latest addition to the Beacon Medical family of products is an excellent high potency CBD option for patients and it will be available to patients, doctors, and hospitals alike."
https://www.newsfilecorp.com/release/104861